Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ABP 938 · Eylea, Eylea Hd

Fusion protein · Inhibitor of Vascular endothelial growth factor-A (VEGFA) and Placental growth factor (PGF) · developed by Regeneron Pharmaceuticals

Approved FDA, Nov 2011

What is ABP 938?

ABP 938 (Pavblu, aflibercept-ayyh) is a biosimilar version of aflibercept, a soluble decoy receptor fusion protein that binds VEGF-A and PlGF and blocks their activation of VEGF receptors on endothelial cells. It is studied in neovascular age-related macular degeneration.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Eylea, Eylea Hd, Pavblu, Yesafili
Drug type
Fusion protein
Targets
Vascular endothelial growth factor-A (VEGFA), Placental growth factor (PGF)
Mechanism
Inhibitor of Vascular endothelial growth factor-A (VEGFA) and Placental growth factor (PGF)
Pathways
angiogenesis, vascular permeability
Therapy area
Ophthalmology
Developer
Regeneron Pharmaceuticals
In trials of
AMGN
FDA status
Approved as Eylea, Eylea Hd, Pavblu (November 18, 2011), BLA125387 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 10, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

nAMDNeovascular Age-related Macular Degeneration

Other drugs acting on VEGFA / PGF

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.